Brain Cancer

Metastatic Breast Cancer

Breast Cancer

Colorectal Cancer

Gastric Cancers

Liver Cancer

Gastrointestinal Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancer

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Gynecologic Cancers

Head and Neck Cancers

Graft-Vs-Host Disease

Leukemia

Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Hematology

Lung Cancer

Pediatric Cancer

Sarcomas

Melanoma

Skin Cancer

Experts outline AE risks—including ICANS, CRS, HLH—as T-cell engager use expands, highlighting the crucial role of nurses and APPs.

Nurses, APPs Key to AE Management as T-Cell Engagers Move Into Solid Tumors

Hope S. Rugo, MD, FASCO, outlined the top considerations for nurses managing toxicities related to PI3K and AKT inhibitors in patients with breast cancer.

PI3K and AKT Inhibitor Toxicity Advice From a Breast Cancer Expert

Adding sonrotoclax to zanubrutinib led to deep and durable response in relapsed or refractory mantle cell lymphoma, according to EHA Congress data.

Sonrotoclax/Zanubrutinib Generates Durable Response in R/R MCL

2025 ICE-T Conference presenters explain what nurses and APPs should take into account as immune cell effector therapies become more widely used.

Q&A: Nursing Considerations From Immune Cell Effector Therapy Experts

News

Latest News

FDA News

Adverse Event Management

Supportive Care

Disparities in Cancer Care

Drug Safety

Radiation Oncology

Survivorship 

Practice Management

Prevention

Contributors

Media

Expert Connections

Morning Rounds

The Vitals

Podcasts

Videos

Between the Lines

From All Angles

Meeting of the Minds

Training Academy

Conferences

Conference Coverage

Conference Listing

Publications

CME/CE

Continuing Education

Resources

Case-Based Digest 

Rx Road Map

Webinars

Cancer Summary Slides

MPN Symptom Management

Events

Subscribe

Partners

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for 

. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

An observational study found IHC may serve as a biomarker for early detection of TP53‐mutant MDS or AML and prediction of TP53 allelic state.

IHC May Sub as NGS for Early TP53-Mutant MDS/AML Detection

Michelle Kirschner, RN, MSN, ACNP, APRN-BC, is a nurse practitioner and director of program development at the Cancer Survivorship and Supportive Care Professionals Network.

Bridget Hoyt is the assistant editor for Oncology Nursing News. She earned her BA in communication studies at Rider University with a minor in public relations. She can be reached at 

Michelle Kirschner, MSN, RN, ACNP, APRN-BC, explains how educating patients about the Breast Cancer Index can support informed endocrine therapy decisions.

Helping Patients Weigh Extended Endocrine Therapy With the BCI

Courtney Moore, APRN, FNP-C, OCN, is a nurse practitioner at Norton Cancer Institute Medical Oncology.

Treatment decisions for older adults after CDK4/6 inhibitors should be tailored, explained Courtney Moore, APRN, FNP-C, OCN.

How to Give Subsequent Therapy for Older Patients With Breast Cancer on CDK4/6 Inhibitors

Gina Mauro currently serves as Vice President of Content at MJH Life Sciences, overseeing 

®. Gina joined the company in 2015 and has held various positions on 

Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com

The addition of avutometinib to defactinib showed promising safety and efficacy for patients with low-grade serous ovarian cancer.

Avutometinib/Defactinib Shows SOC Potential in LG Serous Ovarian Cancer

Oncology Nursing News connects oncology nurses and APPs with updates on therapy advances, side effect management, and patient-centered cancer care.

About Us

Editorial Board

Contact Us

CancerNetwork.com

CureToday.com

OncLive.com

TargetedOnc.com

Advertise

Privacy

Terms & Conditions

Do Not Sell My Information

Oncology Nursing News – Clinical Insights for Cancer Care Nurses

Facebook

LinkedIn

Specialty

Advanced Practice Providers

Clinical

Gynecologic Cancer

Immunotherapy

Nurse Navigation

Quality Improvement

1rem

9th Annual School of Nursing Oncology™

PER's Satellite Symposia at MHS

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Oncology Town Hall™ 2025 ESMO-GI Congress Highlights: The Latest Data on Immune-Based Strategies Across Hepatobiliary Cancers

Sarah C. Rutherford, MD; Matthew Lunning, DO, FACP

Community Practice Connections™: Selecting and Sequencing Therapy for Patients with DLBCL in an Era of Expanding Options

Barbara Pro, MD; Saad Usmani, MD, MBA, FACP, FASCO; Amer Zeidan, MBBS, MHS

8th Annual Live Medical Crossfire®: Hematologic Malignancies

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Peter Robert Galle, MD, PhD; Amit Singal, MD, MS; Linda L. Wong, MD; Ghassan Abou-Alfa, MD, MBA; Han Chong Toh, MD 

Community Practice Connections™: 14th Asia-Pacific Primary Liver Cancer Expert Meeting

Burst CME™: Tackling Adverse Events With Targeted Therapies for Diffuse B-Cell Lymphoma

Matt Lunning DO, FACP; Kami Maddocks, MD; Grzegorz S. Nowakowski, MD, FASCO; Sarah C. Rutherford, MD

Contextualizing Advances in Relapse Refractory DLBCL: Navigating Biomarkers, Emerging Data, and Adverse Event Management to Transform Patient Care

Matt Lunning, DO, FACP; Sarah C. Rutherford, MD

 Biomarkers in Diffuse Large B-Cell Lymphoma: Empowering Treatment Decisions to Improve Outcomes

Matt Lunning, DO, FACP; Grzegorz S. Nowakowski, MD., FASCO

 Treating Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Current Options and Emerging Approaches

Corey Cutler, MD, MPH, FRCP(C); Carrie L. Kitko, MD

BURST Expert Illustrations and Commentaries™: Exploring the Mechanistic Rationale for CSF-1R– Directed Treatment in Chronic GVHD

Sara A. Hurvitz, MD, FACP; Joyce O’Shaughnessy, MD; Heather McArthur, MD, MPH; Hope S. Rugo, MD, FASCO


  Community Practice Connections™: 23rd Annual International Congress on the Future of Breast Cancer West

Asim V. Farooq, MD; Joann Kang, MD; Nita Lee, MD, MPH

(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

20th Annual New York Lung Cancers Symposium®

Richard S. Finn, MD; Anthony B. El-Khoueiry, MD; Pierre Gholam, MD; Lipika Goyal, MD

PER® Liver Cancer Tumor Board: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable HCC Impact Multidisciplinary Patient Management Today… and Tomorrow?

Andre H. Goy, MD; Monique Hartley-Brown, MD, MMSc (Guest Co-Chair); Chiara Battelli, MD, PhD; Marios Giannakis, MD, PhD; Shail Maingi, MD; Aparna Parikh, MD

Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board

Daniel J. DeAngelo, MD, PhD; Claire Roddie, MD, PhD

Advances In™: Taking R/R B-Cell ALL Management to the Next Level With New CAR T Approval

Kathleen N. Moore, MD, MS, FASCO; Susana Banerjee, MBBS, MA, FRCP, PhD; David M. O’Malley, MD; Ritu Salani, MD, MBA

Navigating Low-Grade Serous Ovarian Cancer – Enhancing Diagnosis, Sequencing Therapy, and Contextualizing Novel Advances

Kathleen N. Moore, MD, MS, FASCO; Prof Susana Banerjee, MBBS, MA, FRCP, PhD

Burst CME™: Understanding Novel Advances in LGSOC—A Focus on New Mechanisms of Action and Clinical Trials

Kathleen N. Moore, MD, MS, FASCO; Ritu Salani, MD, MBA

Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care

Mark G. Kris, MD; Justin Gainor, MD; Isabel Preeshagul, DO, MBS; Helena A. Yu, MD

Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies

Kathleen N. Moore, MD, MS, FASCO; David M. O’Malley, MD

Burst CME™: Implementing Appropriate Recognition and Diagnosis of Low-Grade Serous Ovarian Cancer

Burst CME™: How is the Newly Approved CAR T-Cell Therapy Impacting R/R B-Cell ALL Management?

Mark Agulnik, MD; Mrinal M. Gounder, MD; Jacqueline M. Kraveka, DO; Lee M. Zuckerman, MD

Collaborating Across the Continuum®: Identifying and Treating Epithelioid Sarcoma

Tiffany A. Traina, MD, FASCO; Demetria Smith-Graziani, MD, MPH

Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care

Mark Agulnik, MD; Shaina A. Rozell, MD, MPH

 Epithelioid Sarcoma: Applying Clinical Updates to Real Patient Cases

Mark Agulnik, MD; Mrinal M. Gounder, MD; Jacqueline M. Kraveka, DO; Daniel Lefler, MD; Shaina A. Rozell, MD, MPH; Lee M. Zuckerman, MD

Mastering Epithelioid Sarcoma: Enhancing Diagnostic Precision and Tailoring Treatment Strategies

Clinical Showcase™: Selecting the Best Next Steps for a Patient with Epithelioid Sarcoma

Brain Mets: Brain & Spine Metastases Research and Emerging Therapy Conference

2nd Annual Hawaii Cancer Conference

Naval G. Daver, MD; Jessica Altman, MD; Amir T. Fathi, MD; Gail J. Roboz, MD; Joshua Zeidner, MD

Medical Crossfire®: Bridging Evidence to Practice in AML…Updates on FLT3, IDH1/2, Maintenance, Combos, and Clinical Trials

Estelamari Rodriguez, MD, MPH; Millie Das, MD; Ruham Nasany, MD

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Anne Chiang, MD, PhD; J. Douglas Miles, MD, PhD, FAAN; Suma Satti, MD

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Zev A. Wainberg, MD; Manish A. Shah, MD, FASCO; Syma Iqbal, MD

Show Me the Data™: Bridging Clinical Gaps Along the Continuum From Resectable, Early Stage to Advanced Gastric/Gastroesophageal Junction Cancers

19th Annual New York GU Cancers Congress™

Jennifer R. Brown, MD, PhD; Alexey V. Danilov, MD, PhD; Matthew S. Davids, MD, MMSc

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

Stephen V. Liu, MD; Michelle Afkhami, MD; Ignacio I. Wistuba, MD; Helena Yu, MD

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

11th Annual School of Gastrointestinal Oncology® (SOGO®)

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Ghassan Abou-Alfa, MD, MBA

Addressing Unmet Needs in HER2+ Metastatic BTC

Hope S. Rugo, MD, FASCO; Neil M. Iyengar, MD; Komal Jhaveri, MD, FACP

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Shubham Pant, MD, MBBS

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Rachna T. Shroff, MD, MS, FASCO

Proactive Adverse Event Management for HER2+ BTC Treatments

Yana G. Najjar, MD; Douglas B. Johnson, MD, MSCI; Rahul A. Sheth, MD, FSIR 

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

Cindy Neunert, MD, MSCS; Hanny Al-Samkari, MD; Joseph Shatzel, MD, MCR

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

Rami Komrokji, MD; Gabriela Hobbs, MD; John Mascarenhas, MD; Naveen Pemmaraju, MD

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Vinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA; Stephen J. Bagley, MD, MSCE; Angela Waanders, MD, MPH, MS

Upcoming CME Events & Activities

EVENTS

ACTIVITIES

Latest Conference Coverage